- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05874921
uTRACT Jelmyto Registry: Et register over pasienter med øvre del av urinrørskreft (UTUC) behandlet med Jelmyto (uTRACT)
uTRACT Jelmyto Registry: Et multisenter, prospektivt og retrospektivt register for å evaluere virkelige verdenserfaringer og utfall av pasienter med øvre traktus urotelkreft (UTUC) behandlet med Jelmyto
The purpose of this registry is to evaluate real world experience and outcomes of patients with Upper Tract Urothelial Cancer (UTUC) treated with Jelmyto in the United States.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Patients may be enrolled prospectively, at the time of receiving Jelmyto, or after receiving Jelmyto for retrospective data capture and prospective follow up. Patients will be followed until 3 years after the first dose of Jelmyto or death.
Data will be captured to address specific clinical questions and data gaps related to real world use of Jelmyto.
Example clinical questions:
- How is Jelmyto used in the real world setting?
- What adverse events (AEs) and at what rates and time points are they observed in the real world setting?
- What is the disease volume before and after resection/ablation prior to treating with Jelmyto?
- Did the use of Jelmyto impact clinical decision making and management?
- What is the complete response (CR) rate, duration of response, and rate of progression, including subgroups of interest?
- What are the rates of, time to, and pathology at radical nephroureterectomy (RNU) by response to treatment and number of Jelmyto doses received?
- What are outcomes for non-responders or partial responders? What are the rates of surgical and therapeutic treatment options received following response assessment, including additional Jelmyto?
- What was the outcome of patients with solitary kidney and/or chronic kidney disease (CKD)? Did Jelmyto prevent dialysis by avoiding nephrectomy in solitary kidney or in patients with baseline CKD?
- What is the rate and timing of bladder cancer occurrence and/or recurrences?
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiekontakt
- Navn: Michael Louie, MD, MPH, MSc
- Telefonnummer: 855-987-6436
- E-post: registry@urogen.com
Studiesteder
-
-
California
-
Santa Monica, California, Forente stater, 90404
- Rekruttering
- Providence St. Johns Health Center
-
Ta kontakt med:
- Jennifer Linehan, MD
- E-post: Jennifer.linehan@providence.org
-
-
Florida
-
Gainesville, Florida, Forente stater, 32610
- Rekruttering
- University of Florida
-
Ta kontakt med:
- Padraic OMalley, MD
- Telefonnummer: 352-265-8240
- E-post: Padraic.O'Malley@urology.ufl.edu
-
Miami, Florida, Forente stater, 33140
- Rekruttering
- Mount Sinai Medical Center of Florida, Inc.
-
Ta kontakt med:
- Alan Nieder, MD
- E-post: Alan.Nieder@msmc.com
-
Tampa, Florida, Forente stater, 33612
- Rekruttering
- H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc.
-
Ta kontakt med:
- Wade Sexton, MD
- E-post: Wade.Sexton@moffitt.org
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60611
- Rekruttering
- Northwestern University
-
Ta kontakt med:
- Joshua Meeks, MD
- E-post: joshua.meeks@northwestern.edu
-
-
Indiana
-
Indianapolis, Indiana, Forente stater, 46202
- Rekruttering
- Indiana University
-
Ta kontakt med:
- Hristos Kaimakliotis, MD
- E-post: hkaimakl@iupui.edu
-
-
Iowa
-
Iowa City, Iowa, Forente stater, 52242
- Rekruttering
- The State University of Iowa
-
Ta kontakt med:
- Michael ODonnell, MD
- E-post: michael-odonnell@uiowa.edu
-
-
Maryland
-
Baltimore, Maryland, Forente stater, 21287
- Rekruttering
- Johns Hopkins Medical Center
-
Ta kontakt med:
- Nirmish Singla, MD
- Telefonnummer: 410-955-6100
-
Baltimore, Maryland, Forente stater, 21204
- Rekruttering
- Chesapeake Urology
-
Ta kontakt med:
- Rian Dickstein, MD
- E-post: rdickstein@chesuro.com
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02115
- Rekruttering
- Brigham and Women's Hospital
-
Ta kontakt med:
- Christopher Dall, MD
- E-post: cdall@mgb.org
-
Boston, Massachusetts, Forente stater, 02114
- Rekruttering
- Mass General Brigham
-
Ta kontakt med:
- Adam Feldman, MD
- E-post: afeldman@mgb.org
-
-
Michigan
-
Ann Arbor, Michigan, Forente stater, 48109
- Rekruttering
- University of Michigan
-
Ta kontakt med:
- Khurshid Ghani, MD
- E-post: kghani@med.umich.edu
-
-
Missouri
-
Columbia, Missouri, Forente stater, 65211
- Rekruttering
- University of Missouri
-
Ta kontakt med:
- Eliza DeFroda, MD
- E-post: elddmc@health.missouri.edu
-
-
New Jersey
-
New Brunswick, New Jersey, Forente stater, 08903
- Rekruttering
- Rutgers
-
Ta kontakt med:
- Saum Ghodoussipour, MD
- E-post: sg1621@cinj.rutgers.edu
-
-
New York
-
Lake Success, New York, Forente stater, 11042
- Rekruttering
- The Feinstein Institutes for Medical Research
-
Ta kontakt med:
- David Hoenig, MD
- E-post: dhoenig@northwell.edu
-
New York, New York, Forente stater, 10016
- Rekruttering
- NYU Grossman School of Medicine
-
Ta kontakt med:
- Katie Murray, MD
- E-post: Katie.Murray@nyulangone.org
-
Syracuse, New York, Forente stater, 13210
- Rekruttering
- SUNY Upstate
-
Ta kontakt med:
- Joseph Jacob, MD
- E-post: JacobJ@upstate.edu
-
-
North Carolina
-
Chapel Hill, North Carolina, Forente stater, 27599
- Rekruttering
- The University of North Carolina Chapel Hill
-
Ta kontakt med:
- Marc Bjurlin, MD
- E-post: marc_bjurlin@med.unc.edu
-
-
Ohio
-
Columbus, Ohio, Forente stater, 43202
- Rekruttering
- Ohio State University
-
Ta kontakt med:
- Ahmad Shabsigh, MD
- Telefonnummer: 614-685-4263
- E-post: Ahmad.Shabsigh@osumc.edu
-
-
Tennessee
-
Nashville, Tennessee, Forente stater, 37232
- Rekruttering
- Vanderbilt University Medical Center
-
Ta kontakt med:
- Amy Luckenbaugh, MD
- E-post: amy.n.luckenbaugh@vumc.org
-
-
Texas
-
Dallas, Texas, Forente stater, 75390
- Rekruttering
- UT Southwestern Medical Center
-
Ta kontakt med:
- Brett Johnson, MD
- E-post: Brett.Johnson@UTSouthwestern.edu
-
Houston, Texas, Forente stater, 77030
- Rekruttering
- The University of Texas M.D. Anderson Cancer Center
-
Ta kontakt med:
- Surena Matin, MD
- E-post: surmatin@mdanderson.org
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Patients with UTUC who have been treated, are currently undergoing treatment, or will be treated with JELMYTO.
Beskrivelse
Inclusion Criteria:
- Adults >18 years old and capable of giving informed consent.
- Diagnosis of UTUC.
- Receipt of at least 1 dose of JELMYTO after FDA approval (15 Apr 2020).
Exclusion Criteria:
- Incapable of giving informed consent (e.g., incarcerated individuals, individuals with dementia).
- Receipt of 1 or more doses of JELMYTO (also referred to as UGN-101 or Mitogel in clinical development) before FDA approval (on or before 15 Apr 2020).
- Pregnancy or lactation.
- Unable to comply with protocol requirements (for prospective data capture).
- Any medical or mental condition(s) that makes participation in the Registry inadvisable in the opinion of the Investigator (for prospective data capture).
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: COHORT
- Tidsperspektiver: OTHER
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
|---|---|
|
Jelmyto
Patients with UTUC treated with Jelmyto |
The dose of Jelmyto to be instilled is 4 mg per mL via ureteral catheter or a nephrostomy tube, with total instillation volume based on volumetric measurements using pyelography, not to exceed 15 mL (60 mg of mitomycin). Instill Jelmyto once weekly for six weeks. For patients with a complete response 3 months after Jelmyto initiation, Jelmyto instillations may be administered once a month for a maximum of 11 additional instillations.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Rate of No Evidence of Disease (NED) at first evaluation post-treatment (investigator assessment)
Tidsramme: 3 months
|
To evaluate the tumor ablative effect of JELMYTO in the Registry population |
3 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Durability of response at 12, 24, and 36 months in patients who achieve NED after primary treatment with JELMYTO.
Tidsramme: 3 years
|
To evaluate response to JELMYTO treatment in the Registry population |
3 years
|
|
Recurrence free survival after adjuvant treatment with JEMLYTO
Tidsramme: 3 years
|
To evaluate response to JELMYTO treatment in the Registry population |
3 years
|
|
Time to recurrence
Tidsramme: 3 years
|
To evaluate response to JELMYTO treatment in the Registry population |
3 years
|
|
Time to progression
Tidsramme: 3 years
|
To evaluate response to JELMYTO treatment in the Registry population |
3 years
|
|
Incidence of JELMYTO-related AEs
Tidsramme: 3 years
|
To assess the safety of JELMYTO in the Registry population |
3 years
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Yair Lotan, MD, UT Southwestern Medical Center at Dallas
- Hovedetterforsker: Solomon Woldu, MD, UT Southwestern Medical Center at Dallas
- Hovedetterforsker: Adam Feldman, MD, Massachusetts General Hospital
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
- Karsinom
- Neoplasmer
- Tilbakefall
- Antineoplastiske midler
- Enzymhemmere
- Nyre
- UTUC
- TCC
- Nyre
- Urogenitale neoplasmer
- Neoplasmer etter histologisk type
- Mitomycin C
- UGN-101
- Ureteral
- Øvre Tract
- Gel
- Lokalt
- Forlenget utgivelse
- Sakte utgivelse
- Nyresparende
- Neoplasmer etter nettsted
- Alkyleringsmidler
- Urologiske neoplasmer
- Antibiotika, antineoplastisk
- Nukleinsyresyntesehemmere
- Øvre traktus urotelkreft
Ytterligere relevante MeSH-vilkår
- Urogenitale sykdommer
- Patologiske prosesser
- Mannlige urogenitale sykdommer
- Urologiske sykdommer
- Kvinnelige urogenitale sykdommer
- Kvinnelige urogenitale sykdommer og graviditetskomplikasjoner
- Sykdomsattributter
- Neoplasmer, kjertel og epitel
- Patologiske tilstander, tegn og symptomer
- Neoplasmer
- Tilbakefall
- Karsinom
- Urologiske neoplasmer
- Neoplasmer etter histologisk type
- Karsinom, overgangscelle
- Urogenitale neoplasmer
- Neoplasmer etter nettsted
- Organiske kjemikalier
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Heterocykliske forbindelser, 2-ring
- Heterocykliske forbindelser, smeltet ringen
- Indoler
- Kinoner
- Aziriner
- Mitomycins
- Indolekinoner
- Mitomycin
Andre studie-ID-numre
- UT004
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .